Ligand Acquires Myopia Drug Rights in $23M Deal
Ligand agreed to acquire a 100% royalty interest in Santen's myopia drug Ryjunea in Europe and the Middle East for $23 million upfront and will receive tiered royalties on net sales.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed